Immunex Enbrel sBLA Filed July 16; Phase II Data Shows MTX Reduction
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Immunex is seeking an Enbrel (etanercept) indication for "reducing the signs and symptoms of psoriatic arthritis," via an sBLA submitted July 16. The application requests use of the TNF inhibitor both as monotherapy and with methotrexate.